Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (March 2024)
18 slides from Novo Nordisk A/s Class B's investor day presentation, Mar 7, 2024
Slide 1: Cardiovascular and emerging therapy areas
Novo Nordisk® Cardiovascular and emerging therapy areas Martin Holst Lange EVP Development Camilla Sylvest EVP Commercial Strategy and Corporate Affairs 7 MARCH BILL RITCHIE Bill lives with cardiovascular disease USA
Slide 2: Forward-looking statements
2 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2023 and Form 20-F, which both were filed
Slide 3: Strategic aspirations 2025
3 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Strategic aspirations 2025 • Further raise the innovation-bar for diabetes treatment therapeutic focus • Progress towards zero environmental impact • Develop a leading portfolio of superior treatment Innova
Slide 4: Novo Nordisk is expanding into Cardiovascular and emerging therapy areas
4 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Novo Nordisk is expanding into Cardiovascular and emerging therapy areas New therapeutic areas have unmet medical needs Patient overlaps between Novo Nordisk core therapy areas Therapy area Unmet need Obesi
Slide 5: Novo Nordisk has a focused approach in cardiovascular disease
5 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Novo Nordisk has a focused approach in cardiovascular disease Focus areas within cardiovascular disease Atherosclerotic cardiovascular disease Heart failure Heart failure with Transthyretin Systemic Uncontr
Slide 6: Cardiovascular disease clinical pipeline has expanded, leveraging internal and external innovation and synergies
6 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Cardiovascular disease clinical pipeline has expanded, leveraging internal and external innovation and synergies Establishing a presence in CVD Development pipeline Our key focus areas: 2024 2025 2026 2027
Slide 7: Ziltivekimab phase 3 development programme targets high unmet need populations within CVD
7 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Ziltivekimab phase 3 development programme targets high unmet need populations within CVD Atherosclerosis and chronic kidney disease HFmrEF and HFpEF Acute myocardial infarction n = 6,200 n = 5,600 n = 10,0
Slide 8: With the acquisition of ocedurenone, Novo Nordisk moves into uncontrolled hypertension
8 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® With the acquisition of ocedurenone, Novo Nordisk moves into uncontrolled hypertension Uncontrolled hypertension BLOCK-CKD Phase 2 Results 12 weeks after randomisation Unmet need: Hypertension is leading ri
Slide 9: The cardiovascular market is well established with significant and growing healthcare burden
9 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® The cardiovascular market is well established with significant and growing healthcare burden The EU annual economic burden of CVD was estimated to The US annual economic burden of CVD is estimated to exceed
Slide 10: Novo Nordisk will leverage expertise within diabetes and obesity to build presence within cardiovascular disease
10 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Novo Nordisk will leverage expertise within diabetes and obesity to build presence within cardiovascular disease Cardiovascular outcomes trials in Type 2 diabetes and obesity Clinical trials in stand-alone
Slide 11: Commercialisation of late-stage assets will build upon existing commercial efforts with semaglutide
11 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Commercialisation of late-stage assets will build upon existing commercial efforts with semaglutide 2024 2027 2030 Commercial synergies among cardiologist prescribers ILLUSTRATIVE Ocedurenone Ocedurenone Z
Slide 12: Strategy is backed up by an innovative late-stage cardiovascular disease pipeline to address unmet needs
12 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Strategy is backed up by an innovative late-stage cardiovascular disease pipeline to address unmet needs for patients Category Stand-alone cardiovascular assets ASCVD Heart failure ASCVD uHTN HFpEF ATTR-CM
Slide 13: MASH shares a large patient population with Novo Nordisk's core therapy areas
13 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Metabolic dysfunction-associated steatohepatitis shares a large patient population with Novo Nordisk’s core therapy areas New therapeutic areas have high unmet medical needs Patient overlap between Novo No
Slide 14: MASH pipeline development across F2-F4c segments
14 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® MASH pipeline development across F2-F4c segments Establishing a presence in MASH Development pipeline 2024 2025 2026 2027 Our key focus areas ESSENCE, semaglutide 2.4 mg, F2-F3c Part 1 Phase 3 (Part 2) Add
Slide 15: MASH is a progressive disease and semaglutide could be the therapeutic foundation
15 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® MASH is a progressive disease and semaglutide could be the therapeutic foundation Semaglutide showed resolution of MASH with no worsening of Phase 3a ESSENCE trial in MASH fibrosis versus placebo in the ph
Slide 16: Novo Nordisk will focus on F2-F4c with commercial efforts related to awareness, referrals and diagnosis
16 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Novo Nordisk will focus on F2-F4c with commercial efforts related to awareness, referrals and diagnosis ~22 million people are expected to live with Focus areas to establish presence in MASH MASH referrals
Slide 17: Novo Nordisk enters partnerships to enhance diagnosis in MASH
17 Cardiovascular and emerging therapy areas Commercial execution and innovation Novo Nordisk® Novo Nordisk enters partnerships to enhance diagnosis in MASH Partnerships across relevant non-invasive tests Novo Nordisk supports NIT for MASH screening and diagnosis Blood test Clinical guideline develo
Slide 18: Closing remarks
Novo Nordisk® Closing remarks A significant unmet need remains in cardiovascular disease Novo Nordisk has cardiometabolic competencies and is growing a late-stage pipeline in CVD Significant unmet need in MASH Phase 3 results for semaglutide 2.4 mg in MASH expected end 2024 BILL RITCHIE Bill lives w